299P - Eribulin is safe and efficient in metastatic breast cancer in elderly patients. Results from the REPROLINE multicentric retro-prospective cohort

Date 11 September 2017
Event ESMO 2017 Congress
Session Poster display session
Topics Cytotoxic agents
Breast Cancer
Geriatric Oncology
Cancer in Special Situations
Biological therapy
Presenter Jerome MARTIN-BABAU
Citation Annals of Oncology (2017) 28 (suppl_5): v74-v108. 10.1093/annonc/mdx365
Authors J. MARTIN-BABAU1, M. Robert2, V. Seegers3, M. Paillard4, X. Pivot5, C. Gourmelon2, L. Uwer6, C. Korenbaum7, T. Petit8, J. Thery9, M. Som10, C. Lefeuvre-Plesse10, C. Perret11, H. Simon11, A. Hardy-Bessard1, H. Desclos12, H. Bourgeois13, M. Campone2, O. Tredan14, A. Patsouris15
  • 1Medical Oncology, CARIO - Hôpital Privé des Côtes d'Armor, 22190 - Plerin/FR
  • 2Medical Oncology, ICO Institut de Cancerologie de l'Ouest René Gauducheau, 44805 - Saint-Herblain/FR
  • 3Biostatistics, ICO Institut de Cancerologie de l'Ouest Paul Papin, 49100 - Angers/FR
  • 4Medical Oncology, CHU Besançon, Hôpital Jean Minjoz, 25030 - Besançon/FR
  • 5Oncology, CHU Besançon, Hôpital Jean Minjoz, 25030 - Besançon/FR
  • 6Medical Oncology, Institut de Cancérologie de Lorraine - Alexis Vautrin, 54519 - Vandoeuvre les Nancy/FR
  • 7Medical Oncology, CHU Hautepierre, 67200 - Strasbourg/FR
  • 8Medical Oncology, Centre Paul Strauss Centre de Lutte contre le Cancer, 67065 - Strasbourg/FR
  • 9Medical Oncology, Centre Henri Becquerel, 76000 - Rouen/FR
  • 10Medical Oncology, Centre Eugène Marquis, 35000 - Rennes/FR
  • 11Medical Oncology, CHU Brest, 29200 - Brest/FR
  • 12Medical Oncology, C.H. Broussais, 35400 - St. Malo/FR
  • 13Medical Oncology, Clinique Victor Hugo Le Mans, 72000 - Le Mans/FR
  • 14Medical Oncology, Centre Léon Bérard, 69008 - Lyon/FR
  • 15Medical Oncology, Centre Paul Papin, 49100 - Angers/FR



Treating metastatic breast cancer (MBC) in women of 70 years old or more is a frequent problem however few data are available describing the safety and efficacy of chemotherapy in elderly patients. Eribulin is validated for MBC from the 2nd line treatment onwards since two phase III studies. We present here a focus on safety and efficacy of eribulin in patients ≥ 70 years old compared to the results of younger patients in a real life cohort.


From Oct 2014 to Feb 2017, a multicentric retro-prospective study (REPROLINE) was conducted. Data concerning patient, tumor characteristics, previous treatments administered, tolerance, efficacy and outcome of eribulin were retrieved for patients treated in real life for MBC in 12 different French hospitals between Dec 2013 and Jan 2016. Data from 446 MBC patients were collected. This database was splitted in two cohorts: comparing the results from the cohort of 363 patients < 70 years old (group A) to the cohort of 83 patients ≥70 years old or more (group B).


Median age for each cohort was 56.3 and 75.4 years old. Both cohorts had similar tumour characteristics, number of metastatic sites and the median number of prior chemotherapy lines was 2. Albumine serum levels were lower in the group B with 21% of patients with albumine < 30g/L versus 13% in group A, without any statistical difference. Outcomes were similar in group A and B with respectively: median PFS of 3.67 months versus 3.7 months; HR 0.972(CI 95% 0.762-1.241), p = 0.821. median OS 10.7 months vs 10.7 months; HR 0.997 (CI95% 0.752-1.323), p = 0.984. Patients in both groups received a median number of 4 cycles. The most frequent grade 3 adverse events were neutropenia (22.9% in group A and 15.7% in group B), fatigue (6.5% group A and 13.3% group B) and neurotoxicity (4.4% and 3.6%, respectively). No statistical difference between elderly and younger patients was demonstrated. 9.6% of the total patients stopped the treatment due to fatigue.


We present here the first study focusing retro-prospectively on the tolerance and efficacy of eribulin in elderly patients in real life. In this study, eribulin in patients ≥70 years old is as effective and safe as in younger patients.

Clinical trial identification


Legal entity responsible for the study

Anne Patsouris




All authors have declared no conflicts of interest.